SEC Filings

Form F-1
ERYTECH PHARMA S.A. filed this Form F-1 on 10/06/2017
Document Outline
Entire Document (7103.3 KB)
Subdocument 1 - F-1 - F-1
Page 1 - As filed with the United States Securities and Exchange Commission on October 6, 2017.
Page 2 - The information contained in this preliminary prospectus is not complete and may be changed. We may
Page 3 - TABLE OF CONTENTS
Page 4 - EXCHANGE RATE INFORMATION
Page 5 - MARKET, INDUSTRY AND OTHER DATA
Page 6 - PROSPECTUS SUMMARY
Page 7 - Our ERYCAPS Platform Technology
Page 8 - Our Product Development Pipeline
Page 9 - E. coli
Page 10 - Our Strategy
Page 11 - Summary Risk Factors
Page 12 - Implications of Being an Emerging Growth Company
Page 13 - Corporate Information
Page 14 - THE GLOBAL OFFERING
Page 15 - N/A
Page 16 - SUMMARY CONSOLIDATED FINANCIAL DATA
Page 17 - N/A
Page 18 - RISK FACTORS
Page 19 - We may not be successful in our efforts to use and expand our ERYCAPS platform to develop marketable
Page 20 - Risks Related to our Financial Position and Capital Needs
Page 21 - We may be forced to repay conditional advances prematurely if we fail to comply with our contractual
Page 22 - Our product candidates will need to undergo clinical trials that are time-consuming and expensive, t
Page 23 - Delays, suspensions and terminations in our clinical trials could result in increased costs to us an
Page 24 - Changes in regulatory requirements, guidance from regulatory authorities or unanticipated events dur
Page 25 - In the European Union, GRASPA contains a known active substance, which would undermine its data and
Page 26 - We have entered, and may in the future enter into, collaboration agreements with third parties for t
Page 27 - Risks Related to the Commercialization of Our Product Candidates
Page 28 - Even if we successfully complete clinical trials of our product candidates, those candidates may not
Page 29 - Even though we have obtained orphan drug designation from the EMA for eryaspase for the treatment of
Page 30 - Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-contain
Page 31 - Any of our product candidates for which we obtain marketing approval could be subject to post-market
Page 32 - The EMA, FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the
Page 33 - Adverse market and economic conditions may exacerbate certain risks associated with commercializing
Page 34 - Our manufacturing facilities are subject to significant government regulations and approvals. If we
Page 35 - Risks Related to Our Operations
Page 36 - Our business may be exposed to foreign exchange risks.
Page 37 - Our internal computer systems, or those of our third-party contractors or consultants, may fail or s
Page 38 - Our employees may engage in misconduct or other improper activities, including violating applicable
Page 39 - Risks Related to Intellectual Property
Page 40 - Issued patents covering our product candidates could be found invalid or unenforceable if challenged
Page 41 - If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation fo
Page 42 - Third parties may assert ownership or commercial rights to inventions we develop.
Page 43 - Third parties may assert that our employees or consultants have wrongfully used or disclosed confide
Page 44 - The market price of our equity securities may be volatile, and purchasers of our ordinary shares or
Page 45 - After the completion of the global offering, we may be at an increased risk of securities class acti
Page 46 - If you purchase ordinary shares or ADSs in the global offering, you will experience substantial and
Page 47 - The rights of shareholders in companies subject to French corporate law differ in material respects
Page 48 - You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.
Page 49 - Purchasers of ADSs in the U.S. offering may not be directly holding our ordinary shares.
Page 50 - As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and
Page 51 - We are an emerging growth company under the JOBS Act and will be able to avail ourselves of reduced
Page 52 - We must maintain effective internal control over financial reporting, and if we are unable to do so,
Page 53 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 54 - MARKET INFORMATION
Page 55 - USE OF PROCEEDS
Page 56 - N/A
Page 57 - DIVIDEND POLICY
Page 58 - CAPITALIZATION
Page 59 - N/A
Page 60 - DILUTION
Page 61 - N/A
Page 62 - N/A
Page 63 - SELECTED CONSOLIDATED FINANCIAL DATA
Page 64 - Selected Consolidated Statement of Financial Position Data:
Page 65 - MANAGEMENT S DISCUSSION AND ANALYSIS
Page 66 - N/A
Page 67 - Interim Financial Reporting
Page 68 - Research Tax Credit
Page 69 - Operating Expenses
Page 70 - Agreement with Orphan Europe
Page 71 - Results of Operations
Page 72 - General and Administrative Expenses
Page 73 - Financial Income (Loss)
Page 74 - Research and Development Expenses
Page 75 - General and Administrative Expenses
Page 76 - Critical Accounting Policies and Estimates
Page 77 - Share-based payment
Page 78 - Liquidity and Capital Resources
Page 79 - Non-refundable Subsidies and Conditional Advances from BPI France
Page 80 - Contractual Obligations
Page 81 - Capital Expenditures
Page 82 - Foreign Currency Exchange Risk
Page 83 - N/A
Page 84 - BUSINESS
Page 85 - Acute Lymphoblastic Leukemia
Page 86 - Our Additional ERYCAPS Product Candidates
Page 87 - Corporate Information
Page 88 - Our ERYCAPS Platform Technology
Page 89 - Our Product Development Pipeline
Page 90 - Our Lead Product Candidate Eryaspase A Unique Approach to Cancer Treatment
Page 91 - Clinical Development of Eryaspase
Page 92 - Background and Potential for L-asparaginase as a Treatment for Pancreatic Cancer
Page 93 - Endpoints
Page 94 - Completed Phase 1 Clinical Trial of Eryaspase for the Treatment of Pancreatic Cancer
Page 95 - Background and Market for ALL
Page 96 - Limitations of Free-Form L-asparaginase Administration
Page 97 - Endpoints
Page 98 - Completed Phase 1/2 Clinical Trial in Europe in Adults and Children with Relapsed or Refractory ALL
Page 99 - Ongoing Phase 2 Clinical Trial in the Nordic Countries of Europe for Treatment of Patients Allergic
Page 100 - Background and Market for AML
Page 101 - Other ERYCAPS Development Programs
Page 102 - Commercialization
Page 103 - Agreement with Orphan Europe
Page 104 - Intellectual Property
Page 105 - Competition
Page 106 - Erwinaze
Page 107 - Government Regulation
Page 108 - N/A
Page 109 - BLA and FDA Review Process
Page 110 - Other U.S. Regulatory Matters
Page 111 - U.S. Patent Term Restoration and Marketing Exclusivity
Page 112 - European Union Drug Review and Approval
Page 113 - Orphan Drugs
Page 114 - Commission Nationale de l Informatique et des Libert s
Page 115 - Protection of Clinical Trial Subjects
Page 116 - N/A
Page 117 - Other Healthcare Laws and Compliance Requirements
Page 118 - Employees
Page 119 - Facilities
Page 120 - MANAGEMENT
Page 121 - Iman El-Hariry, M.D., Ph.D.
Page 122 - Luc Dochez
Page 123 - Director Independence
Page 124 - Corporate Governance Practices
Page 125 - Remuneration and Appointments Committee
Page 126 - Compensation of Directors and Executive Officers
Page 127 - Limitations on Liability and Indemnification Matters
Page 128 - Founder s Share Warrants (BSPCE)
Page 129 - N/A
Page 130 - Free Shares (AGA)
Page 131 - Stock Options (SO)
Page 132 - CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS
Page 133 - Employment Agreements with Eric Soyer, Jean-Sebastien Cleiftie and Alexander Scheer
Page 134 - Other Arrangements
Page 135 - N/A
Page 136 - PRINCIPAL SHAREHOLDERS
Page 137 - N/A
Page 138 - DESCRIPTION OF SHARE CAPITAL
Page 139 - Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares
Page 140 - Directors Compensation.
Page 141 - Timing of Payment.
Page 142 - Sinking Fund Provisions.
Page 143 - Notice of Annual Shareholders Meetings.
Page 144 - Extraordinary Shareholders Meeting.
Page 145 - Declaration of Crossing of Ownership Thresholds (Article 9 of the Bylaws)
Page 146 - Reduction in Share Capital.
Page 147 - Assignment and Transfer of Shares.
Page 148 - N/A
Page 149 - N/A
Page 150 - N/A
Page 151 - N/A
Page 152 - N/A
Page 153 - N/A
Page 154 - N/A
Page 155 - N/A
Page 156 - Listing
Page 157 - LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY
Page 158 - DESCRIPTION OF AMERICAN DEPOSITARY SHARES
Page 159 - If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currenc
Page 160 - How can ADS holders interchange between certificated ADSs and uncertificated ADSs?
Page 161 - Payment of Taxes
Page 162 - Reclassifications, Recapitalizations and Mergers
Page 163 - pro rata
Page 164 - Your Right to Receive the Ordinary Shares Underlying Your ADSs
Page 165 - SHARES AND ADSs ELIGIBLE FOR FUTURE SALE
Page 166 - Rule 701
Page 167 - MATERIAL UNITED STATES FEDERAL INCOME AND FRENCH TAX CONSIDERATIONS
Page 168 - Material French Tax Considerations
Page 169 - Tax on Sale or Other Disposition
Page 170 - Wealth Tax
Page 171 - Distributions.
Page 172 - Sale, Exchange or Other Taxable Disposition of the ADSs.
Page 173 - N/A
Page 174 - The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urge
Page 175 - ENFORCEMENT OF CIVIL LIABILITIES
Page 176 - UNDERWRITING
Page 177 - Commission and Expenses
Page 178 - No Sales of Similar Securities
Page 179 - Electronic Distribution
Page 180 - NOTICE TO INVESTORS
Page 181 - Australia
Page 182 - investisseurs qualifi s
Page 183 - Switzerland
Page 184 - EXPENSES RELATING TO THE GLOBAL OFFERING
Page 185 - LEGAL MATTERS
Page 186 - WHERE YOU CAN FIND MORE INFORMATION
Page 187 - INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page 188 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 189 - CONSOLIDATED STATEMENTS OF INCOME (LOSS)
Page 190 - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Page 191 - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Page 192 - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY
Page 193 - CONSOLIDATED STATEMENTS OF CASH FLOWS
Page 194 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Page 195 - 3. STATEMENT OF COMPLIANCE
Page 196 - 4. SIGNIFICANT ACCOUNTING POLICIES
Page 197 - 4.5 Use of estimates and judgments
Page 198 - 4.8 Impairment tests
Page 199 - Financial liabilities at the amortized cost
Page 200 - Provisions for risks
Page 201 - Accounting for Government Grants and Disclosure of Government Assistance
Page 202 - Partnership with Orphan Europe
Page 203 - 4.19 Earnings per share
Page 204 - 5. NOTES RELATED TO THE CONSOLIDATED STATEMENT OF INCOME (LOSS)
Page 205 - 5.3 Personnel expenses
Page 206 - Allocation of 3,585 BSA on August 31, 2015.
Page 207 - 2016 Plan
Page 208 - Allocation of 111,261 free shares (AGA2016) on October 3, 2016
Page 209 - Allocation of 45,000 share subscription warrants (BSA2016) on October 3, 2016
Page 210 - 5.6 Income tax
Page 211 - 6.2 Property, plant and equipment
Page 212 - 6.4 Inventories
Page 213 - 6.8 Shareholders equity
Page 214 - 6.9 Provisions
Page 215 - 6.10 Financial liabilities
Page 216 - BPI France / Pancreas
Page 217 - BPI France / GR-SIL
Page 218 - 6.11 Other current liabilities
Page 219 - 6.13 Financial instruments recognized in the consolidated statement of financial position and effect
Page 220 - Liquidity risk
Page 221 - Interest rate risk
Page 222 - Agreement with the Teva Group
Page 223 - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
Page 224 - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Page 225 - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Page 226 - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY
Page 227 - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Page 228 - NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Page 229 - 2. BASIS OF PREPARATION AND STATEMENT OF COMPLIANCE
Page 230 - Use of judgments and estimates
Page 231 - 5.2 Operating expenses by nature
Page 232 - Share-based payments (IFRS 2)
Page 233 - Allocation of 55,000 share subscription warrants (BSA2017) on June 27, 2017
Page 234 - 6 NOTES RELATED TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Page 235 - Other non-current financial assets
Page 236 - Research Tax Credit
Page 237 - 6.7 Financial liabilities
Page 238 - 6.8 Other current liabilities
Page 239 - 7 OFF-BALANCE SHEET COMMITMENTS
Page 240 - ERYTECH Pharma S.A.
Page 241 - PART II
Page 242 - N/A
Page 243 - N/A
Page 244 - SIGNATURES
Page 245 - POWER OF ATTORNEY
Page 246 - SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT
Subdocument 2 - EX-4.1 - EX-4.1
Page 1 - EXHIBIT 4.1
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - American Depositary Shares.
Page 7 - Deliver; Surrender.
Page 8 - Deposited Securities.
Page 9 - Insolvency Event.
Page 10 - Securities Act of 1933.
Page 11 - Deposit of Shares.
Page 12 - Delivery of American Depositary Shares.
Page 13 - Registration of Transfer of American Depositary Shares; Combination and Split-up of Receipts; Interc
Page 14 - Surrender of American Depositary Shares and Withdrawal of Deposited Securities.
Page 15 - Limitations on Delivery, Transfer and Surrender of American Depositary Shares.
Page 16 - However
Page 17 - Filing Proofs, Certificates and Other Information.
Page 18 - Liability of Owner for Taxes.
Page 19 - Warranties on Deposit of Shares.
Page 20 - Cash Distributions.
Page 21 - provided
Page 22 - Rights.
Page 23 - Conversion of Foreign Currency.
Page 24 - Fixing of Record Date.
Page 25 - Voting of Deposited Shares.
Page 26 - Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities.
Page 27 - except that
Page 28 - Termination Option Event
Page 29 - Maintenance of Office and Transfer Books by the Depositary.
Page 30 - Obligations of the Depositary and the Company.
Page 31 - PFIC
Page 32 - The Custodians.
Page 33 - Distribution of Additional Shares, Rights, etc.
Page 34 - indemnified person
Page 35 - Retention of Depositary Documents.
Page 36 - Amendment.
Page 37 - except
Page 38 - No Third Party Beneficiaries.
Page 39 - Appointment of Agent for Service of Process; Submission to Jurisdiction; Jury Trial Waiver.
Page 40 - Waiver of Immunities.
Page 41 - N/A
Page 42 - Company
Page 43 - Receipts
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Page 48 - N/A
Page 49 - Pre-Release
Page 50 - provided
Page 51 - Termination Option Event
Page 52 - N/A
Page 53 - N/A
Page 54 - N/A
Page 55 - N/A
Page 56 - Instruction Cutoff Date
Page 57 - Voluntary Offer
Page 58 - Termination Option Event
Page 59 - N/A
Page 60 - N/A
Page 61 - Termination Date
Page 62 - DRS
Page 63 - N/A
Page 64 - N/A
Subdocument 3 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - PREAMBLE
Page 3 - II- SPECIFIC CONDITIONS
Page 4 - 2.9 Rent Exemption Excluding Tax/Excluding Fees
Page 5 - 2.14 Premises and employees Consumption of fluids and waste production
Page 6 - 4) TERM
Page 7 - 7) MOBILE SCALE
Page 8 - access control digital code, intercom, video monitoring, employee salaries and social security contr
Page 9 - 9) TAX RULES
Page 10 - 10) SECURITY DEPOSIT
Page 11 - 11) LATE PAYMENT INTEREST
Page 12 - 13) MAINTENANCE
Page 13 - 14) DOMICILIATION - SUBLEASING
Page 14 - 16) INSURANCE
Page 15 - N/A
Page 16 - 17) END OF LEASE RETURN OF THE PREMISES
Page 17 - 18) AMENDMENTS - TOLERANCE - INDIVISIBILITY
Page 18 - 22) - LEASE RENEWAL
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - CONSTRUCTION WORK 60 avenue Rockefeller ADENINE 69008 LYON
Page 27 - N/A
Page 28 - MISSION NO. 361847
Page 29 - 1. This report, with respect to obligations, prohibitions, servitudes and requirements set forth wit
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - GLOSSARY
Page 34 - Prescription Decision
Page 35 - PPR Project Established
Page 36 - Decision on Natural or Technological Disasters
Page 37 - FRENCH REPUBLIC
Page 38 - N/A
Page 39 - Article 2
Page 40 - FRENCH REPUBLIC
Page 41 - Decisions on recognition of Natural Disaster
Page 42 - Ministry of Sustainable Development
Subdocument 4 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - PREAMBLE
Page 3 - IT IS THUS AGREED AS FOLLOWS:
Page 4 - Article 6 Renovation work to be completed by the Lessor
Page 5 - N/A
Page 6 - PLAN OF ADDITIONAL LEASED PARKING SPACES
Subdocument 5 - EX-10.3 - EX-10.3
Page 1 - Exhibit 10.3
Page 2 - ***Text Omitted and Filed Separately
Page 3 - ***Text Omitted and Filed Separately
Page 4 - ***Text Omitted and Filed Separately
Page 5 - ***Text Omitted and Filed Separately
Page 6 - ***Text Omitted and Filed Separately
Page 7 - ***Text Omitted and Filed Separately
Page 8 - ***Text Omitted and Filed Separately
Page 9 - ***Text Omitted and Filed Separately
Page 10 - ***Text Omitted and Filed Separately
Page 11 - ***Text Omitted and Filed Separately
Page 12 - ***Text Omitted and Filed Separately
Page 13 - ***Text Omitted and Filed Separately
Page 14 - ***Text Omitted and Filed Separately
Page 15 - ***Text Omitted and Filed Separately
Page 16 - ***Text Omitted and Filed Separately
Page 17 - ***Text Omitted and Filed Separately
Page 18 - ***Text Omitted and Filed Separately
Page 19 - ***Text Omitted and Filed Separately
Page 20 - ***Text Omitted and Filed Separately
Page 21 - ***Text Omitted and Filed Separately
Page 22 - ***Text Omitted and Filed Separately
Page 23 - ***Text Omitted and Filed Separately
Page 24 - ***Text Omitted and Filed Separately
Page 25 - ***Text Omitted and Filed Separately
Page 26 - ***Text Omitted and Filed Separately
Page 27 - ***Text Omitted and Filed Separately
Page 28 - ***Text Omitted and Filed Separately
Page 29 - ***Text Omitted and Filed Separately
Page 30 - ***Text Omitted and Filed Separately
Page 31 - ***Text Omitted and Filed Separately
Page 32 - ***Text Omitted and Filed Separately
Page 33 - ***Text Omitted and Filed Separately
Page 34 - ***Text Omitted and Filed Separately
Page 35 - ***Text Omitted and Filed Separately
Page 36 - ***Text Omitted and Filed Separately
Page 37 - ***Text Omitted and Filed Separately
Page 38 - ***Text Omitted and Filed Separately
Page 39 - ***Text Omitted and Filed Separately
Page 40 - ***Text Omitted and Filed Separately
Page 41 - ***Text Omitted and Filed Separately
Page 42 - ***Text Omitted and Filed Separately
Page 43 - ***Text Omitted and Filed Separately
Page 44 - ***Text Omitted and Filed Separately
Page 45 - ***Text Omitted and Filed Separately
Page 46 - ***Text Omitted and Filed Separately
Page 47 - ***Text Omitted and Filed Separately
Page 48 - ***Text Omitted and Filed Separately
Page 49 - ***Text Omitted and Filed Separately
Page 50 - ***Text Omitted and Filed Separately
Page 51 - ***Text Omitted and Filed Separately
Page 52 - ***Text Omitted and Filed Separately
Page 53 - ***Text Omitted and Filed Separately
Page 54 - ***Text Omitted and Filed Separately
Page 55 - ***Text Omitted and Filed Separately
Page 56 - ***Text Omitted and Filed Separately
Page 57 - ***Text Omitted and Filed Separately
Page 58 - ***Text Omitted and Filed Separately
Page 59 - ***Text Omitted and Filed Separately
Page 60 - ***Text Omitted and Filed Separately
Page 61 - ***Text Omitted and Filed Separately
Page 62 - ***Text Omitted and Filed Separately
Page 63 - ***Text Omitted and Filed Separately
Page 64 - ***Text Omitted and Filed Separately
Page 65 - ***Text Omitted and Filed Separately
Page 66 - ***Text Omitted and Filed Separately
Subdocument 6 - EX-10.4 - EX-10.4
Page 1 - Exhibit 10.4
Page 2 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 3 - SCHEDULE B): Execution versions of the addenda to the Medac Agreements
Page 4 - ADDENDUM N 2 TO
Page 5 - MAA
Page 6 - N/A
Page 7 - N/A
Page 8 - [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OM
Page 9 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 10 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 11 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 12 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 13 - ERYTECH Pharma
Page 14 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 15 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Subdocument 7 - EX-10.5 - EX-10.5
Page 1 - Exhibit 10.5
Page 2 - ***Text Omitted and Filed Separately
Page 3 - ***Text Omitted and Filed Separately
Page 4 - ***Text Omitted and Filed Separately
Page 5 - ***Text Omitted and Filed Separately
Page 6 - ***Text Omitted and Filed Separately
Page 7 - ***Text Omitted and Filed Separately
Page 8 - ***Text Omitted and Filed Separately
Page 9 - ***Text Omitted and Filed Separately
Page 10 - ***Text Omitted and Filed Separately
Page 11 - ***Text Omitted and Filed Separately
Page 12 - ***Text Omitted and Filed Separately
Page 13 - ***Text Omitted and Filed Separately
Page 14 - ***Text Omitted and Filed Separately
Page 15 - ***Text Omitted and Filed Separately
Page 16 - ***Text Omitted and Filed Separately
Page 17 - ***Text Omitted and Filed Separately
Page 18 - ***Text Omitted and Filed Separately
Page 19 - ***Text Omitted and Filed Separately
Page 20 - ***Text Omitted and Filed Separately
Page 21 - ***Text Omitted and Filed Separately
Page 22 - ***Text Omitted and Filed Separately
Page 23 - ***Text Omitted and Filed Separately
Page 24 - ***Text Omitted and Filed Separately
Page 25 - ***Text Omitted and Filed Separately
Page 26 - ***Text Omitted and Filed Separately
Page 27 - ***Text Omitted and Filed Separately
Page 28 - ***Text Omitted and Filed Separately
Page 29 - ***Text Omitted and Filed Separately
Page 30 - ***Text Omitted and Filed Separately
Page 31 - ***Text Omitted and Filed Separately
Page 32 - ***Text Omitted and Filed Separately
Page 33 - ***Text Omitted and Filed Separately
Page 34 - ***Text Omitted and Filed Separately
Page 35 - ***Text Omitted and Filed Separately
Page 36 - ***Text Omitted and Filed Separately
Page 37 - ***Text Omitted and Filed Separately
Page 38 - ***Text Omitted and Filed Separately
Page 39 - ***Text Omitted and Filed Separately
Page 40 - ***Text Omitted and Filed Separately
Page 41 - ***Text Omitted and Filed Separately
Subdocument 8 - EX-10.6 - EX-10.6
Page 1 - Exhibit 10.6
Page 2 - ***Text Omitted and Filed Separately
Page 3 - ***Text Omitted and Filed Separately
Page 4 - ***Text Omitted and Filed Separately
Page 5 - ***Text Omitted and Filed Separately
Page 6 - ***Text Omitted and Filed Separately
Page 7 - ***Text Omitted and Filed Separately
Page 8 - ***Text Omitted and Filed Separately
Page 9 - ***Text Omitted and Filed Separately
Page 10 - ***Text Omitted and Filed Separately
Page 11 - ***Text Omitted and Filed Separately
Page 12 - ***Text Omitted and Filed Separately
Page 13 - ***Text Omitted and Filed Separately
Page 14 - ***Text Omitted and Filed Separately
Page 15 - ***Text Omitted and Filed Separately
Subdocument 9 - EX-10.7 - EX-10.7
Page 1 - Exhibit 10.7
Page 2 - ***Text Omitted and Filed Separately
Page 3 - ***Text Omitted and Filed Separately
Page 4 - ***Text Omitted and Filed Separately
Page 5 - ***Text Omitted and Filed Separately
Page 6 - ***Text Omitted and Filed Separately
Page 7 - ***Text Omitted and Filed Separately
Page 8 - ***Text Omitted and Filed Separately
Page 9 - ***Text Omitted and Filed Separately
Page 10 - ***Text Omitted and Filed Separately
Page 11 - ***Text Omitted and Filed Separately
Page 12 - ***Text Omitted and Filed Separately
Page 13 - ***Text Omitted and Filed Separately
Page 14 - ***Text Omitted and Filed Separately
Page 15 - ***Text Omitted and Filed Separately
Page 16 - ***Text Omitted and Filed Separately
Page 17 - ***Text Omitted and Filed Separately
Page 18 - ***Text Omitted and Filed Separately
Page 19 - ***Text Omitted and Filed Separately
Page 20 - ***Text Omitted and Filed Separately
Page 21 - ***Text Omitted and Filed Separately
Page 22 - ***Text Omitted and Filed Separately
Subdocument 10 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - MAA
Page 3 - N/A
Page 4 - B)
Subdocument 11 - EX-10.9 - EX-10.9
Page 1 - Exhibit 10.9
Page 2 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 3 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 4 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 5 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 6 - ERYTECH Pharma
Page 7 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Page 8 - [***] = CONFIDENTIAL TREATMENT REQUESTED
Subdocument 12 - EX-10.10 - EX-10.10
Page 1 - Exhibit 10.10
Page 2 - ***Text Omitted and Filed Separately
Page 3 - ***Text Omitted and Filed Separately
Page 4 - ***Text Omitted and Filed Separately
Page 5 - ***Text Omitted and Filed Separately
Page 6 - ***Text Omitted and Filed Separately
Page 7 - ***Text Omitted and Filed Separately
Page 8 - ***Text Omitted and Filed Separately
Page 9 - ***Text Omitted and Filed Separately
Page 10 - ***Text Omitted and Filed Separately
Page 11 - ***Text Omitted and Filed Separately
Page 12 - ***Text Omitted and Filed Separately
Page 13 - ***Text Omitted and Filed Separately
Page 14 - ***Text Omitted and Filed Separately
Page 15 - ***Text Omitted and Filed Separately
Page 16 - ***Text Omitted and Filed Separately
Page 17 - ***Text Omitted and Filed Separately
Page 18 - ***Text Omitted and Filed Separately
Page 19 - ***Text Omitted and Filed Separately
Page 20 - ***Text Omitted and Filed Separately
Page 21 - ***Text Omitted and Filed Separately
Page 22 - ***Text Omitted and Filed Separately
Page 23 - ***Text Omitted and Filed Separately
Page 24 - ***Text Omitted and Filed Separately
Page 25 - ***Text Omitted and Filed Separately
Page 26 - ***Text Omitted and Filed Separately
Page 27 - ***Text Omitted and Filed Separately
Page 28 - ***Text Omitted and Filed Separately
Page 29 - ***Text Omitted and Filed Separately
Page 30 - ***Text Omitted and Filed Separately
Subdocument 13 - EX-10.11 - EX-10.11
Page 1 - Exhibit 10.11
Page 2 - D O
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - Company
Page 8 - Directeur G n ral
Subdocument 14 - EX-10.12 - EX-10.12
Page 1 - Exhibit 10.12
Subdocument 15 - EX-10.13 - EX-10.13
Page 1 - Exhibit 10.13
Subdocument 16 - EX-10.14 - EX-10.14
Page 1 - Exhibit 10.14
Page 2 - SUMMARY
Page 3 - ERYTECH PHARMA SA
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - Where the exercise of an Option would lead the Company to be liable for any payment, whether due to
Page 10 - bulletin de souscription ou d achat
Page 11 - Operation
Page 12 - Change of Control
Page 13 - N/A
Page 14 - ERYTECH PHARMA
Page 15 - N/A
Page 16 - ERYTECH PHARMA
Page 17 - Where the exercise of an Option would lead the Company to be liable for any payment, whether due to
Page 18 - N/A
Subdocument 17 - EX-10.15 - EX-10.15
Page 1 - Exhibit 10.15
Page 2 - TABLE OF CONTENTS
Page 3 - Company
Page 4 - Tranches
Page 5 - 5.1. Administration
Page 6 - 8.1. Allotment decision
Page 7 - N/A
Page 8 - 9.2. Delivery of the Securities
Page 9 - T
Page 10 - Operation
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - APPENDIX A
Page 15 - T
Page 16 - APPENDIX B
Subdocument 18 - EX-21.1 - EX-21.1
Page 1 - Exhibit 21.1
Subdocument 19 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Top